港股異動丨創新藥概念爆發 樂普生物-B升超7% 年內累升1.18倍
創新藥概念股樂普生物-B(2157.HK)午後強勢拉昇,一度升7.71%至5.73港元,年內累升1.18倍,遠遠跑贏大盤表現(同期恒指累升超16%),也跑贏了行業平均表現(同期恒生香港上市生物科技指數累升超47%)。消息面上,樂普生物-B昨日晚間公吿,公司已向聯交所上市委員會申請批准54,268,364股H股(經轉換H股)上市及准許買賣。聯交所已於2025年6月19日授出上市批准。高盛表示,生物技術授權交易激增驅動板塊重估,預期這一勢頭將持續,更多交易即將達成。CDMO/CRO或迎來二階投資機會,具有更高後期和商業化製造敞口的公司展現更強韌的盈利能力。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.